PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.…
PRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a Hearing
PRF Technologies (NASDAQ: PRFX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 0.4758 USD on 20 November 2026, down 89.3% over 52 weeks. Its 52-week range is 0.4600 USD to 7.950 USD: the price is 94.0% below the high and 3.4% above the low.
Its market capitalisation is 1.66M USD.
PRF Technologies reports return on equity of -58.8%.
It holds more cash than debt, a net cash position of 11.48M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.